Investors Buy Large Volume of SELLAS Life Sciences Group Call Options (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the recipient of some unusual options trading on Thursday. Stock investors bought 57,085 call options on the stock. This is an increase of 29% compared to the average daily volume of 44,315 call options.

Institutional Trading of SELLAS Life Sciences Group

Hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC lifted its position in SELLAS Life Sciences Group by 293.2% during the third quarter. GAMMA Investing LLC now owns 2,186 shares of the company’s stock worth $27,000 after acquiring an additional 1,630 shares during the last quarter. California State Teachers Retirement System grew its position in shares of SELLAS Life Sciences Group by 22.4% in the first quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock valued at $39,000 after purchasing an additional 1,709 shares during the last quarter. Nykredit A S acquired a new position in shares of SELLAS Life Sciences Group in the second quarter valued at approximately $27,000. Sterling Capital Management LLC increased its stake in shares of SELLAS Life Sciences Group by 900.8% during the third quarter. Sterling Capital Management LLC now owns 6,635 shares of the company’s stock worth $82,000 after purchasing an additional 5,972 shares during the period. Finally, The Manufacturers Life Insurance Company increased its stake in shares of SELLAS Life Sciences Group by 20.2% during the first quarter. The Manufacturers Life Insurance Company now owns 45,691 shares of the company’s stock worth $193,000 after purchasing an additional 7,673 shares during the period. Institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Stock Down 2.2%

NASDAQ:SLS opened at $10.15 on Friday. SELLAS Life Sciences Group has a 12-month low of $1.39 and a 12-month high of $15.88. The firm has a market capitalization of $2.05 billion, a price-to-earnings ratio of -48.33 and a beta of 2.56. The stock’s 50 day moving average price is $12.23 and its two-hundred day moving average price is $8.54.

SELLAS Life Sciences Group (NASDAQ:SLS) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01).

Analyst Ratings Changes

SLS has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Thursday, October 15th. Alliance Global Partners restated a “buy” rating on shares of SELLAS Life Sciences Group in a report on Wednesday, August 12th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, SELLAS Life Sciences Group has a consensus rating of “Hold” and a consensus price target of $10.00.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies. The company’s research and development programs are centered on treatments designed to stimulate or restore the immune system’s ability to recognize and attack cancer cells, as well as targeted therapies for hematologic malignancies.

SELLAS’ lead product candidate is galinpepimut-S (GPS), a multi-peptide immunotherapeutic targeting Wilms’ tumor 1 (WT1), a protein expressed in multiple types of cancer.